Skip Ribbon Commands
Skip to main content

News

 

 

NICE PUBLISHES NEW GUIDANCE SUPPORTING THE USE OF HOLMIUM-166 SELECTIVE INTERNAL RADIATION THERAPY FOR UNRESECTABLE ADVANCED HEPATOCELLULAR CARCINOMAhttps://www.terumo-europe.com/en-emea/news/nice-publishes-new-guidance-supporting-the-use-of-holmium-166-selective-internal-radiation-therapy-for-unresectable-advanceNICE PUBLISHES NEW GUIDANCE SUPPORTING THE USE OF HOLMIUM-166 SELECTIVE INTERNAL RADIATION THERAPY FOR UNRESECTABLE ADVANCED HEPATOCELLULAR CARCINOMA2/07/2024 22:00:00<h4>​Terumo Europe delighted to share that a positive guidance has been published by NICE mentioning that Holmium-166 Selective Internal Radiation Therapy (SIRT) using QuiremSpheres<sup>TM</sup> microspheres is recommended as an option for treating HCC patients with child-Pugh grade A liver impairment, when conventional transarterial therapies are inappropriate. ​​<br></h4>
NICE publishes a guidance supporting the use of Selective Internal Radiation Therapy for neuroendocrine tumors with liver metastasishttps://www.terumo-europe.com/en-emea/news/nice-publishes-a-guidance-supporting-the-use-of-selective-internal-radiation-therapy-for-neuroendocrine-tumors-with-liver-mNICE publishes a guidance supporting the use of Selective Internal Radiation Therapy for neuroendocrine tumors with liver metastasis16/05/2024 22:00:00<h4>​<br><br></h4><h4>Terumo Europe is delighted to share that a positive guidance has been published by NICE stating that Selective Internal Radiation Therapy (SIRT) is now recommended to be used for the treatment of neuroendocrine tumors with liver metastasis (NELM).<br></h4><h4>This is a key milestone as it expands the existing treatment options (surgery, percutaneous ablation, systemic therapies, peptide receptor radionuclide therapy (PRRT) & other intra-arterial therapies) for the treatment of patients with NELM.  ​<br></h4>
Launch BioPearlTM microspheres, the first resorbable drug-eluting microsphereshttps://www.terumo-europe.com/en-emea/news/launch-biopearltm-microspheres-the-first-resorbable-drug-eluting-microspheresLaunch BioPearlTM microspheres, the first resorbable drug-eluting microspheres28/04/2024 22:00:00<h4>Terumo Europe N.V. is pleased to announce the launch of BioPearl<sup>TM</sup> microspheres, the first resorbable drug-eluting microspheres. We are continuing our commitment to advancing TACE by adding our latest innovation and to expanding your TACE therapeutic options. BioPearl<sup>TM</sup> microspheres are designed to combine the confidence from the drug-eluting microspheres technology and the benefits of a resorbable agent.​​​<br></h4>
Launch of new multi-center study investigating resorbable drug-eluting microspheres safety and efficacyhttps://www.terumo-europe.com/en-emea/news/launch-of-new-multi-center-study-investigating-resorbable-drug-eluting-microspheres-safety-and-efficacyLaunch of new multi-center study investigating resorbable drug-eluting microspheres safety and efficacy10/03/2024 23:00:00<p><span lang="EN-GB" style="font-family:"segoe ui", sans-serif;">​</span><span lang="EN-GB" style="font-family:"segoe ui", sans-serif;">Terumo Europe N.V. announces the launch of the BIOPEARL-ONE study, a new multi-center post market clinical trial: BioPearl<sup>TM</sup> microspheres are loaded with doxorubicin to treat patients with unresectable hepatocellular carcinoma (HCC). A prospective, single arm, multi-centre post-market follow-up study is intended to assess the safety and efficacy of BioPearl<sup>TM</sup> microspheres loaded with doxorubicin in the treatment of patients with unresectable HCC. </span>​<br></p>
Terumo expands global presence with new subsidiary in South-Africahttps://www.terumo-europe.com/en-emea/news/terumo-expands-global-presence-with-new-subsidiary-in-south-africaTerumo expands global presence with new subsidiary in South-Africa29/11/2023 23:00:00<p>Terumo Corporation (TSE: 4543) today announced the establishment of Terumo South Africa (Pty) Ltd. (Terumo South Africa), its newest subsidiary in South-Africa. This strategic move represents a significant milestone in the company’s continued commitment to expanding its global footprint and strengthening its presence in key growing markets.​<br></p>
ANGIO-SEAL™ VIP & FEMOSEAL™ VASCULAR CLOSURE DEVICES SECURED CE CERTIFICATE UNDER THE NEW MEDICAL DEVICE REGULATIONhttps://www.terumo-europe.com/en-emea/news/angio-seal™-vip-femoseal™-vascular-closure-devices-secured-ce-certificate-under-the-new-medical-device-regulationANGIO-SEAL™ VIP & FEMOSEAL™ VASCULAR CLOSURE DEVICES SECURED CE CERTIFICATE UNDER THE NEW MEDICAL DEVICE REGULATION3/10/2023 22:00:00<p>Terumo (TSE: 4543) is proud to announce that both of our Vascular Closure Devices, Angio-Seal™ VIP & Femoseal™, received the EU MDR certifications.​<br></p>